Discussion about this post

User's avatar
Hansang Bae's avatar

Question: "Why is this small randomized study making the mainstream news?"

Answer: Because they buy ads.

Asked and answered. NEXT!!!

Florent Beuyet's avatar

Your point about the control arm is the one that keeps nagging at me. In a 122-person unblinded trial, observation with hydroxyurea as the comparator means the survival gap — 14.7 to 24 months — is doing a lot of work against a control that isn't really a treatment arm in the modern maintenance sense. Add the moving pieces you flag — the planned 140 shrinking to 122, a single overall-survival analysis at 80 deaths, and follow-up quietly stretched from 52 weeks to five years on the registry — and the headline number starts to look less like a result and more like a hypothesis waiting for a properly powered, placebo-controlled test. I hope it replicates; AML maintenance is exactly where an off-the-shelf peptide vaccine would be transformative if real. But the Washington Post treatment of a small open-label study as near-breakthrough is precisely the pattern that burns patients and clinicians alike when the confirmatory trial lands differently.

5 more comments...

Ready for more?